Karyopharm reports preliminary FY2023 total revenue ~$146M, XPOVIO net product revenue ~$112M, meeting guidance

Karyopharm Therapeutics Inc.

2023-FY EPS reported -$1.25 revenue$146,033,000

Full year 2023 total revenue ~$145.9M; U.S. XPOVIO net product revenue ~$112.0M; Q4 total revenue ~$33.6M.
Cash and investments ~$192M as of Dec 31, 2023, enabling cash runway into late 2025.
Key 2023 achievements include NCCN guideline upgrade for XVd, patent extension to Jul 2033, and ~20% workforce reduction.
Near-term catalysts: Phase 3 readouts in 2H 2024 for multiple myeloma, enrollment completion in EC-042 for endometrial cancer, and updated myelofibrosis data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Karyopharm Therapeutics Inc. reported fourth quarter and full year 2023 results: revenue approximately $146 million.

Period: fourth quarter and full year 2023
Revenue: approximately $146 million
Result: preliminary results

Exact text from the filing

Endometrial Cancer and Myelofibrosis – – Preliminary Unaudited Full Year 2023 Total Revenue and U.S. XPOVIO ® (selinexor) Net Product Revenue Expected to be Approximately $146 Million and $112 Million, Respectively, Meeting Company’s Guidance – – Potential for Selinexor to be a Novel Maintenance Treatment for Patients with TP53 Wild-Type Endometrial Cancer

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-003978

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.